Lilly's Retatrutide Shows Promise
Eli Lilly's Retatrutide posts strong phase 3 results, potentially boosting the company's pipeline. This may impact the biotech sector.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.